Trimethoprim/sulfamethoxazole
Trimethoprim/sulfamethoxazole, sold under the trade names Bactrim, Cotrim and Septra, among others, is a fixed-dose combination antibiotic medication used to treat a variety of bacterial infections. It consists of one part trimethoprim to five parts sulfamethoxazole. It is used to treat urinary tract infections, methicillin-resistant Staphylococcus aureus skin infections, travelers' diarrhea, respiratory tract infections, and cholera, among others. It is used both to treat and prevent pneumocystis pneumonia and toxoplasmosis in people with HIV/AIDS and other causes of immunosuppression. It can be given orally or intravenous infusion.
Trimethoprim/sulfamethoxazole is on the World Health Organization's List of Essential Medicines. It is available as a generic medication. In 2023, it was the 128th most commonly prescribed medication in the United States, with more than 4million prescriptions.
Medical uses
Trimethoprim/sulfamethoxazole generally kills bacteria, by blocking the microorganisms' ability to make and to use folate.''Pneumocystis jirovecii'' pneumonia
Trimethoprim/sulfamethoxazole is the medicine most commonly used to prevent Pneumocystis jirovecii pneumonia People who get Pneumocystis pneumonia have a medical condition that weakens their immune system, like HIV/AIDS, or take medicines that reduce the body's ability to fight bacterial and viral infections. People with HIV/AIDS are less likely to get Pneumocystis pneumonia as a result of antiretroviral therapy. However, Pneumocystis pneumonia is still a substantial public health problem. Most of what is scientifically known about Pneumocystis pneumonia and its treatment comes from studying people with HIV/AIDS.Susceptibility
Organisms against which trimethoprim/sulfamethoxazole can be effective include:Acinetobacter spp.Aeromonas spp.Alcaligenes/''Achromobacter spp.Bartonella henselaeBordetella pertussis Brucella spp.Burkholderia cepaciaBurkholderia mallei Burkholderia pseudomallei Chlamydia spp.Chryseobacterium meningosepticumCitrobacter spp.Enterobacter spp.Enterococcus spp.Escherichia coliHaemophilus spp.Hafnia alveiKingella spp.Klebsiella granulomatisKlebsiella pneumoniaeLegionella spp.Listeria monocytogenes Moraxella catarrhalisMorganella morganiiMycobacterium tuberculosis Neisseria gonorrhoeae Neisseria meningitidis Nocardia spp.Plesiomonas shigelloidesPneumocystis jiroveciiProteus mirabilisProteus vulgarisProvidencia rettgeriProvidencia stuartiiSalmonella typhi- Non-typhi
Pregnancy and breast feeding
Its use during pregnancy is contraindicated, although it has been placed in Australian pregnancy category C. Its use during the first trimester and 12 weeks prior to pregnancy has been associated with an increased risk of congenital malformations, especially malformations associated with maternal folic acid deficiency such as neural tube defects such as spina bifida, cardiovascular malformations, urinary tract defects, oral clefts, and club foot in epidemiological studies. Its use later on during pregnancy also increases the risk of preterm labour and low birth weight. Animal studies have yielded similarly discouraging results.It appears to be safe for use during breastfeeding as long as the baby is healthy.
Infants
Its use in those less than 2 months of age is not recommended due to the risk of adverse side effects.Adverse effects
Common side effects include nausea, vomiting, rash, and diarrhea. Severe allergic reactions and Clostridioides difficile infection may occasionally occur. Its use in pregnancy is not recommended. It appears to be safe for use during breastfeeding as long as the baby is healthy.A recent study supported previous case reports that the treatment of teens or young adults with trimethoprim/sulfamethoxazole can cause serious adverse results. The study found that the 30-day risk of developing potentially lethal respiratory failure in patients aged 10 to 25 years who were treated with trimethoprim/sulfamethoxazole was significantly higher than those in this age group who were treated with either amoxicillin or a cephalosporin. These findings supported the FDA warning on using trimethoprim/sulfamethoxazole. Overall, the study suggested that this risk of respiratory failure should be carefully weighed against the benefits of using this trimethoprim/sulfamethoxazole drug combination in individuals 10 to 25 years old.
Contraindications
Contraindications include the following:- Known hypersensitivity to trimethoprim, sulphonamides or any other ingredients in the formulations
- Pregnancy
- Severe liver failure, marked liver parenchymal damage, or jaundice.
- Serious haematological disorders and porphyria.
- Severe chronic kidney disease where repeated measurements of the plasma concentration cannot be performed
Interactions
Its use is advised against in people being concomitantly treated with:- ACE inhibitors like captopril, enalapril, lisinopril, perindopril, and ramipril due to the potential for additive hyperkalaemic effects
- Prilocaine — additive risk of methaemoglobinaemia
- Antiarrhythmics like amiodarone and dofetilide
- Antibacterials like dapsone, methenamine and rifampicin
- Anticoagulants like warfarin and acenocoumarol — anticoagulant effects of either drug is potentiated by this combination
- Sulfonylureas — effects enhanced
- Phenytoin, half-life of phenytoin is increased
- Antifolates like pyrimethamine, proguanil and methotrexate increase the risk of associated side effects like bone marrow toxicity, folic acid supplementation should be considered. A significant risk of megaloblastic anaemia exists with doses of pyrimethamine in excess of 25 mg/wk.
- Antivirals, more specifically, lamivudine, zalcitabine and zidovudine
- Procainamide and/or amantadine may have their plasma concentrations increased bilaterally or unilaterally.
- Clozapine and other antipsychotics — increased risk of haematological side effects
- Nucleoside analogue antineoplastics like azathioprine and mercaptopurine — increased risk of haematological toxicity
- Digoxin — increase in digoxin levels in a proportion of elderly patients
- Diuretics — elderly patients receiving thiazide diuretics are at a heightened risk for developing thrombocytopaenia while on co-trimoxazole
- Ciclosporin — patients who have received a kidney transplant and are receiving co-trimoxazole and ciclosporin concomitantly are at an increased risk of having a reversible deterioration in their kidney function.
- Spironolactone — concurrent use can increase the likelihood of hyperkalemia, especially in the elderly. The trimethoprim portion acts to prevent potassium excretion in the distal tubule of the nephron.
- Potassium aminobenzoate — effects of sulfonamides inhibited.
- Laboratory tests — trimethoprim and sulfonamides have been reported to interfere with diagnostic tests, including serum-methotrexate and elevated serum creatinine levels, also urea, urinary glucose and urobilinogen tests.
Overdose
Likely signs of toxicity include:- Nausea
- Vomiting
- Dizziness
- Headache
- Mental depression
- Confusion
- Thrombocytopenia
- Uremia
- Bone marrow depression
- Loss of appetite
- Colic
- Drowsiness
- Unconsciousness
- Administration of activated charcoal
- Stomach pumping
- General supportive measures
- Haemodialysis, which is moderately effective in clearing co-trimoxazole from the plasma.
- Calcium folinate treatment in cases of blood dyscrasias
- Forcing oral fluids
Pharmacology
The synergy between trimethoprim and sulfamethoxazole was first described in the late 1960s. Trimethoprim and sulfamethoxazole have a greater effect when given together than when given separately, because they inhibit successive steps in the folate synthesis pathway. They are given in a one-to-five ratio in their tablet formulations so that when they enter the body their concentration in the blood and tissues is roughly one-to-twenty — the exact ratio required for a peak synergistic effect between the two.Sulfamethoxazole, a sulfonamide, induces its therapeutic effects by interfering with the de novo synthesis of folate inside microbial organisms such as protozoa, fungi and bacteria. It does this by competing with p-aminobenzoic acid in the biosynthesis of dihydrofolate.
Trimethoprim serves as a competitive inhibitor of dihydrofolate reductase, hence inhibiting the de novo synthesis of tetrahydrofolate, the biologically active form of folate.
Tetrahydrofolate is crucial in the synthesis of purines, thymidine, and methionine which are needed for the production of DNA and proteins during bacterial replication.
The effects of trimethoprim causes a backlog of dihydrofolate and this backlog can work against the inhibitory effect the drug has on tetrahydrofolate biosynthesis. This is where the sulfamethoxazole comes in; its role is in depleting the excess DHF by preventing it from being synthesised in the first place.
Co-trimoxazole was claimed to be more effective than either of its components individually in treating bacterial infections, although this was later disputed.
Society and culture
Brand names
Trimethoprim/sulfamethoxazole may be abbreviated as SXT, SMZ-TMP, TMP-SMX, TMP-SMZ, or TMP-sulfa. The generic British Approved Name Co-trimoxazole is used for trimethoprim/sulfamethoxazole manufactured and sold by many different companies.The following list of brand names is incomplete:
- Bactrim, Bactrimel
- Bactrom
- Bibactin
- Biseptol
- Sumetrolim
- Co-trimoxazole
- Cotrim
- Deprim
- Diseptyl
- Graprima Forte Kaplet
- Infectrin, Bactrim
- Novo-Trimel
- Primadex
- Primotren
- Resprim
- Sanprima
- Septra
- Septram
- Septran
- Septrin
- Sulfatrim
- Teva-Trimel
- Trisul
- Vactrim